Telomir Pharmaceuticals Inc. Common Stock

TELO | NASDAQ

Price Alert Chart Builder DCF Calculator

$1.27

+$0.03 (+2.42%)

Sep 22, 2026, 12:23 PM ET · Market open

Overview Rating Statistics Financials Earnings Analysts Ownership Profile

+2.42%

(1D)

Rating

Updated: Aug 18, 2026

18.5

Fundamentals Weak

Market Sentiment Neutral

Moat None

Full Analysis

Key Statistics

Market Data

Market Cap $87.34M

1D Range

1.21 1.29

52W Range

0.89 2.09

Valuation (TTM)

PE -1.36

PB 16.94

EV/EBITDA -19.30

Valuation (NTM)

Forward PE N/A

Forward PEG -0.02

Price Target $4

Cash Flow

FCF Yield -5.8%

SBC Adj. FCF Yield -5.2%

SBC Impact -10.2%

Margins

Gross Margin 0.0%

Operating Margin 0.0%

FCF Margin N/A

Growth (CAGR)

Revenue 3Y | 5Y N/A | N/A

Dil EPS 3Y | 5Y -17.8% | N/A

FCF 3Y | 5Y 16.8% | N/A

Returns

ROA -109.5%

ROE -102.7%

ROIC -120.9%

Financial Health

Net Cash

$5.17M

Current Ratio 16.14

Interest Coverage -867.98

Dividends

Div Yield N/A

Payout Ratio N/A

FCF Payout Ratio N/A

All Key Statistics

Loading financial charts...

Profile

Telomir Pharmaceuticals, Inc. operates as a preclinical-stage pharmaceutical firm, concentrating its efforts on creating and launching novel therapeutic interventions. Its primary focus involves the d...

Sector Healthcare

Industry Biotechnology

Employees 2

IPO Date Feb 8, 2024

Website telomirpharma.com

Fiscal Year January - December

Full Company Profile

Latest News

No news articles available yet.

Earnings

Next Earnings

Dec 2, 2026

EPS Est

Pro

Rev Est

Pro

Earnings Details ➞